GMAB News and Press, Genmab A/S From 01/06/20

The stock market and equity investors love growth. The ability of a company to grow revenues with strong momentum is typically a sign of a hot product or service in high demand that is capturing market share. Among the fastest growing companies, consideration for measures like profitability or...

Company Announcement Genmab and CureVac enter broad strategic partnership Companies to conduct joint research on first program; option for Genmab to initiate three additional programs during 5-year research term Genmab will provide CureVac with a USD 10 million upfront payment ...

Copenhagen-based Genmab A/S ( GMAB +0.1% ) inks a five-year research collaboration and license agreement with German biotech CureVac AG aimed at developing mRNA-based antibody therapies for cancer. More news on: Genmab A/S, Healthcare stocks news, Read more ...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 11/13/2019. Please visit our Tracking Ole Andreas Halvorsen&#...

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Johnson & Johnson (NYSE: JNJ ) unit Janssen Biotech's Darzalex (daratumumab), combined with Takeda's (NYSE: TAK ) Velcade (bortezomib), thalidomide and dexamethasone, for the tre...

The following slide deck was published by Genmab A/S in conjunction with this Read more ...

As expected, the European Commission approves the use of Johnson & Johnson ( JNJ -0.2% ) unit Janssen Biotech's Darzalex (daratumumab), combined with Celgene's Revlimid (lenalidomide) and dexamethasone, for the treatment of adults with newly diagnosed multiple myeloma who are ineligi...

Genmab A/S (NASDAQ: GMAB ): Q3 GAAP EPS of DKK8.28. More news on: Genmab A/S, Genmab A/S, Genmab A/S, Earnings news and commentary, Healthcare stocks news, Read more ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to...

Creating a list of companies that will make my elite list of 2029 investments that will have increased in value by a factor of 10 or more is a major challenge for more than one reason. As I stated in my previous article, in our fast moving world, industries unknown today may be household names...